To the full analysis
Buyback calculator for Dianthus Therapeutics
Dianthus Therapeutics stock: key metrics
DNTHDianthus Therapeutics had an operating margin of −8,739.3% and a return on invested capital (ROIC) of −32.9% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2016 | no data | no data | no data |
| 2017 | no data | no data | no data |
| 2018 | no data | no data | no data |
| 2019 | no data | no data | no data |
| 2020 | no data | no data | no data |
| 2021 | 100.0% | −886.6% | −888.1% |
| 2022 | 100.0% | −462.9% | −443.8% |
| 2023 | 100.0% | −1,704.7% | −1,541.2% |
| 2024 | 100.0% | −1,633.7% | −1,362.8% |
| 2025 | 100.0% | −8,739.3% | −7,973.3% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2016 | −100.0% | −81.0% | −83.2% |
| 2017 | −70.5% | −95.1% | −65.2% |
| 2018 | −39.5% | −48.0% | −36.6% |
| 2019 | −54.4% | −44.5% | −47.5% |
| 2020 | −52.1% | −41.8% | −46.4% |
| 2021 | −7.6% | −6.3% | −6.9% |
| 2022 | −38.7% | −18.5% | −34.3% |
| 2023 | −25.8% | −31.1% | −24.3% |
| 2024 | −24.1% | −30.6% | −22.7% |
| 2025 | −32.9% | −32.9% | −30.6% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2019)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.